Expanded Access [11C] Methionine PET Imaging

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's treatment.

Primary Objective

To provide expanded access to L-\[11C\]methionine as a positron-emitting tracer in children and young adults for the positron emission tomography (PET) imaging of neoplasms of the central nervous system (CNS) and head and neck to guide therapeutic management of disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging Brain Tumors With FACBC and Methionine

NCT00597246

Brain Cancer CNS Cancer

COMPLETED NA

Methionine PET/CT Studies In Patients With Cancer

NCT00840047

Brain Tumors and/or Solid Tumors Including Brain Stem Glioma High Grade CNS Tumors +11 more

ACTIVE_NOT_RECRUITING PHASE2

Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas

NCT02585219

Glioblastoma

UNKNOWN

[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors

NCT00832598

Brain Cancer Gliomas

COMPLETED NA

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases

NCT05408871

Cancer Head Neck Metastatic Cancer Metastatic Lung Cancer

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants receive an intravenous injection of a small (tracer) dose of L-\[11C\]methionine. Approximately 10 minutes later, patients undergo PET scanning to evaluate localization of the tracer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Nervous System Tumor Head and Neck Neoplasms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-(11C) methionine

Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

methionine C 11

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All participants under the care of a SJCRH physician with known or suspected neoplastic disease of the CNS or head and neck are eligible for participation.
* No limit on age.
* Patients of all genders and all ethnic groups under the care of a SJCRH physician.
* Female participants of child-bearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.
* Informed consent signed by participant, parent, or guardian according to the guidelines of the Institutional Review Board.